Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
1 clinical trials · Condition
◉ Watch Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
| Record | Firm | Date |
|---|---|---|
| Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (NCT02315326) | Memorial Sloan Kettering Cancer Center | 2014-12-08 |
Track Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) automatically
Every clearance here is in the API, with alerts when new ones post.